(NASDAQ: TARS) Tarsus Pharmaceuticals's forecast annual revenue growth rate of 44.16% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Tarsus Pharmaceuticals's revenue in 2025 is $233,674,000.On average, 4 Wall Street analysts forecast TARS's revenue for 2025 to be $16,450,674,497, with the lowest TARS revenue forecast at $15,093,656,656, and the highest TARS revenue forecast at $17,574,975,479. On average, 3 Wall Street analysts forecast TARS's revenue for 2026 to be $23,136,946,216, with the lowest TARS revenue forecast at $17,852,689,586, and the highest TARS revenue forecast at $28,139,455,373.
In 2027, TARS is forecast to generate $29,286,233,972 in revenue, with the lowest revenue forecast at $28,208,778,864 and the highest revenue forecast at $30,363,689,080.